Effects of Vildagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on the Parameters of Glucose Metabolism and the Cardio-Ankle Vascular Index in Individuals with Type 2 Diabetes

Daiji Nagayama,Hidetoshi Kawana,Yasuhiro Watanabe,Osamu Horikawa,Masahiro Ohira,Atsuhito Saiki

DOI: https://doi.org/10.3390/jcm13020481

IF: 3.9

2024-01-16

Journal of Clinical Medicine

Abstract:DPP-4 inhibitors are frequently used as first-line agents for the treatment of type 2 diabetes in Japan. This study aimed to examine the effects of vildagliptin on glucose metabolism and arterial stiffness. Twenty treatment-naïve patients with type 2 diabetes (8 males and 12 females) received vildagliptin 50 mg twice daily for 6 months. Self-monitored blood glucose measurements and a 75 g OGTT were performed. Arterial stiffness was assessed using the CAVI. After the vildagliptin treatment, a significant decrease in the median HbA1c (from 8.3 to 6.4%) and fasting HOMA-β (from 26.1 to 34.5%), and a marginally significant decrease in the CAVI (from 8.9 to 8.4, p = 0.087) were observed. The glycemic variability parameters also improved, whereas the insulin sensitivity and oxidative stress remained unchanged. Participants with a lower glycemic variability on the 75 g OGTT after vildagliptin treatment showed a significant decrease in their CAVI. The baseline BMI was significantly higher for the participants with a decreased CAVI than in those with no change in their CAVI (24.5 vs. 20.8 kg/m2). After vildagliptin treatment, a decrease in the CAVI was observed, especially in the individuals with improved glycemic variability on the 75 g OGTT. Vildagliptin may be suitable for vascular protection in individuals with high glycemic variability and/or an elevated BMI.

medicine, general & internal

What problem does this paper attempt to address?

This paper aims to explore the effects of Vildagliptin on glycemic metabolism parameters and arterial stiffness (assessed by the cardiovascular ankle index CAVI) in patients with type 2 diabetes. Specifically, the researchers hope to understand whether Vildagliptin can improve glycemic control in patients with type 2 diabetes and whether it can have a positive impact on vascular health, especially for those with significant blood glucose fluctuations or higher body mass index (BMI).

The research background mentions that dipeptidyl peptidase-4 (DPP-4) inhibitors are commonly used as first-line treatment for type 2 diabetes in Japan, although their role in preventing cardiovascular diseases remains controversial. Therefore, this study not only focuses on the effects of Vildagliptin on glycemic control but also examines its impact on arterial stiffness to evaluate its potential role in cardiovascular protection.